European equities traded in the US as American depositary receipts started the week off higher late Monday morning, rising 0.32% to 1,343.34 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and Grifols (GRFS), which rose 4.3% and 3.9% respectively. They were followed by medical device maker EDAP TMS (EDAP) and pharmaceutical company Ascendis Pharma (ASND), which increased 3.1% and 2.7% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 18% and 3.1% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and petroleum refiner Equinor (EQNR), which were down 2.8% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which advanced 8.6% and 5% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Amarin (AMRN), which were up 4.6% and 2.4% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which dropped 3.7% and 2.2% respectively. They were followed by oil and gas company BP (BP) and insurance company Prudential (PUK), which lost 2.1% and 1.1% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。